Magne D,Angoulvant A,Botterel F,et al. Pneumocystosis: a network survey in the Paris area 2003-2008[J]. Eur J Clin Microbiol Infect Dis,2011,30（5）：673-675.
Morris A,Norris KA. Colonization by Pneumocystis jirovecii and Its Role in Disease[J]. Clin Microbiol Rev,2012,25（2）：297-317.
[6]
Ernst E,Girndt M,Pliquett RU. A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis[J]. BMC Nephrol,2014,15（1）：28.
[7]
Sato M,Ito S,Ogura M,et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome[J]. Pediatr Nephrol,2013,28（1）：145-149.
[8]
Tanaka M,Sakai R,Koike R,et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors[J]. Mod Rheumatol,2012,22（6）：849-858.
[9]
Riebold D,Enoh DO,Kinge TN,et al. Pneumocystis jirovecii colonisation in HIV-positive and HIV-negative subjects in Cameroon[J]. Trop Med Int Health,2014,19（6）：643-655.
[10]
Fong S,Daly KR,Tipirneni R,et al.Antibody Responses against Pneumocystis jirovecii in Health Care Workers Over Time[J]. Emerg Infect Dis,2013,19（10）：1613-1620.
[11]
Debourgogne A,Favreau S,Ladrière M,et al. Characteristics of Pneumocystis pneumonia in Nancy from January 2007 to April 2011 and focus on an outbreak in nephrology[J]. J Mycol Med,2014,24（1）：19-24.
[12]
Seymour JF. Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines[J]. Ann Hematol,2013,92（11）：1569-1570.
[13]
Roblot F,Le Moal G,Kauffmann-Lacroix C,et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment[J]. Scand J Infect Dis,2014,46（3）：210-214.
[14]
Daly KR,Fichtenbaum CJ,Tanaka R,et al. Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons[J]. J Infect Dis,2002,186（5）：644-651.
[15]
Djawe K,Daly KR,Vargas SL,et al. Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein[J]. Int J Infect Dis,2010,14（12）: e1060-e1066.
[16]
Peglow SL,Smulian AG,Linke MJ,et al. Serologic responses to Pneumocystis carinii antigens in health and disease[J]. J Infect Dis,1990,161（2）：296-306.
[17]
Roths JB,Sidman CL. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient SCID mice[J]. Infect Immun,1993,61（5）：1641-1649.
[18]
Wells J,Gigliotti F,Simpson-Haidaris PJ,et al. Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to streptococcus pneumoniae surface antigen PspA[J]. Infect Immun,2004,72（3）：1548-1556.
[19]
Wells J,Haidaris CG,Wright TW,et al. Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia[J]. Infect Immun,2006,74（1）：390-393.
